Cargando…
Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
BACKGROUND: Clinical benefit of axitinib as a first line agent to treat patients with metastatic renal cell carcinoma (mRCC), or locally advanced renal cell carcinoma (RCC) have not been clearly demonstrated. The aim of this study was to evaluate the efficacy and safety of axitinib as first-line the...
Autores principales: | Koie, Takuya, Ohyama, Chikara, Yoneyama, Takahiro, Yamamoto, Hayato, Imai, Atsushi, Hatakeyama, Shingo, Hashimoto, Yasuhiro, Yoneyama, Tohru, Tobisawa, Yuki, Mori, Kazuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417199/ https://www.ncbi.nlm.nih.gov/pubmed/25887125 http://dx.doi.org/10.1186/s12894-015-0027-4 |
Ejemplares similares
-
Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report
por: Koie, Takuya, et al.
Publicado: (2013) -
Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer
por: Koie, Takuya, et al.
Publicado: (2014) -
Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis
por: Koie, Takuya, et al.
Publicado: (2014) -
Safety of heparin bridging therapy for transrectal ultrasound-guided prostate biopsy in patients requiring temporary discontinuation of antithrombotic agents
por: Hamano, Itsuto, et al.
Publicado: (2016) -
Renal Function Outcomes and Risk Factors for Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer
por: Hatakeyama, Shingo, et al.
Publicado: (2016)